Ibex Investors’s Genomic Health, Inc. GHDX Stock Holding History

Ibex Investors’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,482	Closed	-$224K	–	157
2018 Q4	$224K	Buy	+3,482	New	+$244K	0.04%	92

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ibex Investors's GHDX Position: Q1 2019 in Review

Ibex Investors sold out of Genomic Health, Inc. (GHDX) in Q1 2019, closing a stake of 3,482 shares — an estimated $224K sold.

Ibex Investors first reported a position in GHDX in Q4 2018 and held it in 1 quarter. The position peaked at $224K in Q4 2018. 267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

Ibex Investors reported no remaining Genomic Health, Inc. position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 3,482 Genomic Health, Inc. shares in Q1 2019, an estimated $224K.
Ibex Investors first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 1 quarter.
Ibex Investors's Genomic Health, Inc. position peaked at $224K in Q4 2018.
267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.